Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

Judith Anne W Chapman, Lois E. Shepherd, James N. Ingle, Hyman B. Muss, Kathleen I. Pritchard, Karen A. Gelmon, Timothy J. Whelan, Catherine Elliott, Paul E. Goss

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Baseline patient and tumor characteristics differentially affected type of death in the MA.17 placebo-controlled letrozole trial where cardiovascular death was not separately identified. The MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type (OT) of death. MA.27 was a phase III adjuvant breast cancer trial of exemestane versus anastrozole. Effects of baseline patient and tumor characteristics were tested for whether factors were associated with (1) all cause mortality and (2) cause-specific mortality. We also fit step-wise forward cause-specific-adjusted models. 7576 women (median age 64 years; 5417 (72%)<70 years and 2159 (28%) C 70 years) were enrolled and followed for median 4.1 years. The 432 deaths comprised 187 (43%) BC, 66 (15%) cardiovascular, and 179 (41%) OT. Five baseline factors were differentially associated with type of death. Older patients had greater BC (p = 0.03), cardiovascular (p<0.001), and other types (p<0.001) of mortality. Patients with pre-existing cardiovascular history had worse cardiovascular mortality (p<0.001); those with worse ECOG performance status had worse OT mortality (p<0.001). Patients with T1 tumors (p<0.001) and progesterone receptor positive had less BC mortality (p<0.001). Fewer BC deaths occurred with node-negative disease (p<0.001), estrogen receptor-positive tumors (p = 0.001), and without adjuvant chemotherapy (p = 0.005); worse cardiovascular mortality (p = 0.01), with trastuzumab; worse OT mortality, for non-whites (p = 0.03) and without adjuvant radiotherapy (p = 0.003). Overall, 57% of deaths in MA.27 AI-treated patients were non-breast cancer related. Baseline patient and tumor characteristics differentially affected type of death with women 70 or older experiencing more non-breast cancer death.

Original languageEnglish (US)
Pages (from-to)343-349
Number of pages7
JournalBreast Cancer Research and Treatment
Volume156
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Mortality
Neoplasms
exemestane
letrozole
Adjuvant Radiotherapy
Progesterone Receptors
Adjuvant Chemotherapy
Estrogen Receptors
History
Placebos

Keywords

  • Breast cancer death
  • Cardiovascular death
  • Competing risks
  • Elderly

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chapman, J. A. W., Shepherd, L. E., Ingle, J. N., Muss, H. B., Pritchard, K. I., Gelmon, K. A., ... Goss, P. E. (2016). Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Research and Treatment, 156(2), 343-349. https://doi.org/10.1007/s10549-016-3761-8

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. / Chapman, Judith Anne W; Shepherd, Lois E.; Ingle, James N.; Muss, Hyman B.; Pritchard, Kathleen I.; Gelmon, Karen A.; Whelan, Timothy J.; Elliott, Catherine; Goss, Paul E.

In: Breast Cancer Research and Treatment, Vol. 156, No. 2, 2016, p. 343-349.

Research output: Contribution to journalArticle

Chapman, JAW, Shepherd, LE, Ingle, JN, Muss, HB, Pritchard, KI, Gelmon, KA, Whelan, TJ, Elliott, C & Goss, PE 2016, 'Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27', Breast Cancer Research and Treatment, vol. 156, no. 2, pp. 343-349. https://doi.org/10.1007/s10549-016-3761-8
Chapman, Judith Anne W ; Shepherd, Lois E. ; Ingle, James N. ; Muss, Hyman B. ; Pritchard, Kathleen I. ; Gelmon, Karen A. ; Whelan, Timothy J. ; Elliott, Catherine ; Goss, Paul E. / Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. In: Breast Cancer Research and Treatment. 2016 ; Vol. 156, No. 2. pp. 343-349.
@article{17a31e5a4ae34049b9ce5b5c3c5ac9f4,
title = "Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27",
abstract = "Baseline patient and tumor characteristics differentially affected type of death in the MA.17 placebo-controlled letrozole trial where cardiovascular death was not separately identified. The MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type (OT) of death. MA.27 was a phase III adjuvant breast cancer trial of exemestane versus anastrozole. Effects of baseline patient and tumor characteristics were tested for whether factors were associated with (1) all cause mortality and (2) cause-specific mortality. We also fit step-wise forward cause-specific-adjusted models. 7576 women (median age 64 years; 5417 (72{\%})<70 years and 2159 (28{\%}) C 70 years) were enrolled and followed for median 4.1 years. The 432 deaths comprised 187 (43{\%}) BC, 66 (15{\%}) cardiovascular, and 179 (41{\%}) OT. Five baseline factors were differentially associated with type of death. Older patients had greater BC (p = 0.03), cardiovascular (p<0.001), and other types (p<0.001) of mortality. Patients with pre-existing cardiovascular history had worse cardiovascular mortality (p<0.001); those with worse ECOG performance status had worse OT mortality (p<0.001). Patients with T1 tumors (p<0.001) and progesterone receptor positive had less BC mortality (p<0.001). Fewer BC deaths occurred with node-negative disease (p<0.001), estrogen receptor-positive tumors (p = 0.001), and without adjuvant chemotherapy (p = 0.005); worse cardiovascular mortality (p = 0.01), with trastuzumab; worse OT mortality, for non-whites (p = 0.03) and without adjuvant radiotherapy (p = 0.003). Overall, 57{\%} of deaths in MA.27 AI-treated patients were non-breast cancer related. Baseline patient and tumor characteristics differentially affected type of death with women 70 or older experiencing more non-breast cancer death.",
keywords = "Breast cancer death, Cardiovascular death, Competing risks, Elderly",
author = "Chapman, {Judith Anne W} and Shepherd, {Lois E.} and Ingle, {James N.} and Muss, {Hyman B.} and Pritchard, {Kathleen I.} and Gelmon, {Karen A.} and Whelan, {Timothy J.} and Catherine Elliott and Goss, {Paul E.}",
year = "2016",
doi = "10.1007/s10549-016-3761-8",
language = "English (US)",
volume = "156",
pages = "343--349",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

AU - Chapman, Judith Anne W

AU - Shepherd, Lois E.

AU - Ingle, James N.

AU - Muss, Hyman B.

AU - Pritchard, Kathleen I.

AU - Gelmon, Karen A.

AU - Whelan, Timothy J.

AU - Elliott, Catherine

AU - Goss, Paul E.

PY - 2016

Y1 - 2016

N2 - Baseline patient and tumor characteristics differentially affected type of death in the MA.17 placebo-controlled letrozole trial where cardiovascular death was not separately identified. The MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type (OT) of death. MA.27 was a phase III adjuvant breast cancer trial of exemestane versus anastrozole. Effects of baseline patient and tumor characteristics were tested for whether factors were associated with (1) all cause mortality and (2) cause-specific mortality. We also fit step-wise forward cause-specific-adjusted models. 7576 women (median age 64 years; 5417 (72%)<70 years and 2159 (28%) C 70 years) were enrolled and followed for median 4.1 years. The 432 deaths comprised 187 (43%) BC, 66 (15%) cardiovascular, and 179 (41%) OT. Five baseline factors were differentially associated with type of death. Older patients had greater BC (p = 0.03), cardiovascular (p<0.001), and other types (p<0.001) of mortality. Patients with pre-existing cardiovascular history had worse cardiovascular mortality (p<0.001); those with worse ECOG performance status had worse OT mortality (p<0.001). Patients with T1 tumors (p<0.001) and progesterone receptor positive had less BC mortality (p<0.001). Fewer BC deaths occurred with node-negative disease (p<0.001), estrogen receptor-positive tumors (p = 0.001), and without adjuvant chemotherapy (p = 0.005); worse cardiovascular mortality (p = 0.01), with trastuzumab; worse OT mortality, for non-whites (p = 0.03) and without adjuvant radiotherapy (p = 0.003). Overall, 57% of deaths in MA.27 AI-treated patients were non-breast cancer related. Baseline patient and tumor characteristics differentially affected type of death with women 70 or older experiencing more non-breast cancer death.

AB - Baseline patient and tumor characteristics differentially affected type of death in the MA.17 placebo-controlled letrozole trial where cardiovascular death was not separately identified. The MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type (OT) of death. MA.27 was a phase III adjuvant breast cancer trial of exemestane versus anastrozole. Effects of baseline patient and tumor characteristics were tested for whether factors were associated with (1) all cause mortality and (2) cause-specific mortality. We also fit step-wise forward cause-specific-adjusted models. 7576 women (median age 64 years; 5417 (72%)<70 years and 2159 (28%) C 70 years) were enrolled and followed for median 4.1 years. The 432 deaths comprised 187 (43%) BC, 66 (15%) cardiovascular, and 179 (41%) OT. Five baseline factors were differentially associated with type of death. Older patients had greater BC (p = 0.03), cardiovascular (p<0.001), and other types (p<0.001) of mortality. Patients with pre-existing cardiovascular history had worse cardiovascular mortality (p<0.001); those with worse ECOG performance status had worse OT mortality (p<0.001). Patients with T1 tumors (p<0.001) and progesterone receptor positive had less BC mortality (p<0.001). Fewer BC deaths occurred with node-negative disease (p<0.001), estrogen receptor-positive tumors (p = 0.001), and without adjuvant chemotherapy (p = 0.005); worse cardiovascular mortality (p = 0.01), with trastuzumab; worse OT mortality, for non-whites (p = 0.03) and without adjuvant radiotherapy (p = 0.003). Overall, 57% of deaths in MA.27 AI-treated patients were non-breast cancer related. Baseline patient and tumor characteristics differentially affected type of death with women 70 or older experiencing more non-breast cancer death.

KW - Breast cancer death

KW - Cardiovascular death

KW - Competing risks

KW - Elderly

UR - http://www.scopus.com/inward/record.url?scp=85007021323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007021323&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3761-8

DO - 10.1007/s10549-016-3761-8

M3 - Article

C2 - 27006189

AN - SCOPUS:85007021323

VL - 156

SP - 343

EP - 349

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -